Rising Prevalence Of Liver Diseases Fueling The Growth Of The Market Due To Increasing Cases Of NAFLD And Alcohol-Related Liver Conditions: Transformative Forces Shaping the Obeticholic Acid Market Landscape in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Obeticholic Acid Industry Market Size Be by 2025?
The surge in the size of the obeticholic acid market has been significant in recent years. The market is projected to increase from $0.9 billion in 2024 to $1.01 billion in 2025, with a compound annual growth rate (CAGR) of 12.3%. Factors such as the growing prevalence of primary biliary cholangitis (PBC), a higher incidence of non-alcoholic steatohepatitis (NASH), burgeoning healthcare infrastructure in developing markets, increased liver disease detection and screening, rising healthcare spending, and investments in liver disease research have contributed to the growth recorded in the historic period.

What's the Long-Term Growth Forecast for the Obeticholic Acid Market Size Through 2029?
The market value of obeticholic acid is predicted to escalate rapidly in the coming years, reaching an estimated "$1.64 billion by 2029" with a CAGR of 12.8%. The forecasted growth can be associated with factors such as the rising incidence of primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH), the increasing need for advance treatments for liver diseases, expanding knowledge about liver diseases and their treatments, advancements in worldwide healthcare services in developing nations, and heightened consciousness about liver diseases and available therapies. Key trends during this period are expected to include the utilization of obeticholic acid for NASH treatment, strategic alliances for further advancement, the use of digital health technologies for tracking and adherence, a pivot towards non-alcoholic fatty liver disease (NAFLD) treatment, progression in liver disease biomarkers, and diagnostic technologies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/obeticholic-acid-global-market-report

What Are the Key Growth Drivers Fueling the Obeticholic Acid Market Expansion?
An increase in liver-related diseases is anticipated to speed up the obeticholic acid market's growth. Liver diseases, which impair the proper functioning of the liver, are seeing a surge due to the overconsumption of alcohol. This high intake of alcohol can trigger liver inflammation, cirrhosis, and even liver failure by damaging liver cells and compromising the organ's operational efficiency. Obeticholic acid mitigates this effect for liver disease patients by triggering the farnesoid X receptor (FXR), which in turn reduces bile acid build-up, decreases liver inflammation, and slows the course of fibrosis, thereby enhancing liver function overall. For instance, the Office for Health Improvement and Disparities, a UK-based government body, reported in December 2024 that the count of premature fatalities due to alcoholic liver disease rose by 3.6% in 2023, peaking at 5,984 from 5,776 in 2022. As a result, the increasing occurrence of liver diseases is fuelling the growth of the obeticholic acid market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22079&type=smp

What Long-Term Trends Will Define the Future of the Obeticholic Acid Market?
Major players in the obeticholic acid sector are focused on bringing to market groundbreaking products like farnesoid X receptor (FXR) agonists, in an effort to optimize treatment for liver diseases and improve patient prognosis. FXR agonists are substances that stimulate the FXR, a nuclear receptor that helps manage bile acid metabolism, inflammation, and fibrosis in the liver. These FXR agonists are instrumental in enhancing liver functionality and are employed in addressing health issues such as primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). A case in point is that in February 2024, Intercept Pharmaceuticals Inc, a biopharmaceutical firm originating in the US, revealed that its supplemental New Drug Application (sNDA) for Ocaliva, a drug intended to treat PBC patients was approved by the U.S. Food and Drug Administration (FDA). This FDA approval for the supplemental sNDA of obeticholic acid (Ocaliva) represents a regulatory milestone in corroborating its curative benefits in treating PBC.

How Is the Obeticholic Acid Market Segmented?
The obeticholic acid market covered in this report is segmented -

1) By Product Type: Tablets, Capsules, Other Product Types
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By Application: Primary Biliary Cholangitis, Nonalcoholic Steatohepatitis, Other Applications

Subsegments:

1) By Tablets: Immediate-Release Tablets, Extended-Release Tablets
2) By Capsules: Soft Gelatin Capsules, Hard Gelatin Capsules
3) By Other Product Types: Oral Suspensions, Injectable Formulations

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=22079&type=smp

Which Companies Are Leading the Charge in Obeticholic Acid Market Innovation?
Major companies operating in the obeticholic acid market are Pfizer Inc., GlaxoSmithKline (GSK), Gilead Sciences Inc., Amgen Inc., Genfit, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals, WuXi AppTec, Bayer AG, Sumitomo Dainippon Pharma Co. Ltd., Horizon Therapeutics, Dr. Reddy's Laboratories, Lupin Limited, Hepalink Pharmaceutical Group5, Alembic Pharmaceuticals, Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals, Viva Life sciences, Omgene Life Sciences Pvt. Ltd., Zydus Cadila

Which Regions Are Leading the Global Obeticholic Acid Market in Revenue?
North America was the largest region in the Obeticholic Acid market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the obeticholic acid market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22079

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.